Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

16
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
16
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

20
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
20
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

195
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
195
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiome modulations After kidney transplantation (ENIGMA): study protocol of a prospective longitudinal trial.

BMJ open·2026
Same author

A Slc5a6-Deficient Mouse Model Reveals Metabolically Driven Cardiomyopathy with Therapeutic Potential for Vitamin-Based Intervention.

JCI insight·2026
Same author

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Journal of Crohn's & colitis·2026
Same author

Association of nasopharyngeal <i>Dolosigranulum pigrum</i> and <i>Corynebacterium</i> species with post-acute sequelae of SARS-CoV-2 in a longitudinal cohort.

Microbiology spectrum·2026
Same author

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Gene Panel Analysis Through Genotyping or Sequencing in Pharmacogenetics.

Fundamental & clinical pharmacology·2026
Same author

Socio-Emotional, Behavior and Cognitive Disorders Associated with Exposure to Trace Metals: A Cross-Sectional Pilot Study in School-Age Children in Haut-Katanga Province.

Children (Basel, Switzerland)·2025

Related Experiment Video

Updated: Feb 19, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?

Laure Elens1,2, Vincent Haufroid2,3

  • 1Department of Integrated PharmacoMetrics, PharmacoGenomics & PharmacoKinetics, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.

Pharmacogenomics
|November 3, 2017
PubMed
Summary

Incorporating the CYP3A4*22 genotype alongside CYP3A5*3 improves pharmacogenetics classification. This enhanced CYP3A genotype approach offers better discriminative power for clinical guidelines.

Keywords:
CYP3A4*22CYP3A5*3discriminant analysis of principal componentdosage guidelinesgenotypekidney transplantationtacrolimus

More Related Videos

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.1K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K

Related Experiment Videos

Last Updated: Feb 19, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

11.1K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K

Area of Science:

  • Pharmacogenetics
  • Genetics
  • Clinical Pharmacology

Background:

  • The CYP3A5*3 genotype is a key factor in pharmacogenetics, influencing drug metabolism.
  • Current classification systems may benefit from refinement for improved clinical application.

Purpose of the Study:

  • To evaluate the clinical relevance of incorporating CYP3A4*22 genotype information into existing CYP3A5*3-based classifications.
  • To determine if a combined CYP3A genotype (CYP3A5 + CYP3A4) offers superior predictive value.

Main Methods:

  • Discriminant analysis of principal component was employed to assess genotype classification relevance.
  • Pharmacokinetic parameters were analyzed using a linear combination of noncompartmental analysis.
  • The discriminative power of CYP3A5*3 alone versus combined CYP3A genotypes was compared.

Main Results:

  • The combined CYP3A genotype classification demonstrated superior results compared to using CYP3A5*3 alone.
  • Significant differences in pharmacokinetic variables were observed with CYP3A genotype clustering (p=0.04).
  • Canonical plots and receiver operating characteristic curves confirmed the enhanced discriminative power of the combined CYP3A genotype approach.

Conclusions:

  • Incorporating the CYP3A4*22 genotype into clinical practice is strongly recommended to refine existing pharmacogenetics guidelines.
  • This refined approach, particularly for the Caucasian population, can lead to more precise drug response predictions.